Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of GSK3915393 in Healthy Participants
NCT06625489Phase 1Completed
- Sponsor
- GSK
- Start
- Oct 2024
- Primary completion
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of GSK3915393 in idiopathic pulmonary fibrosis (IPF) (4 arms), sponsored by GSK. Primary endpoints: Number of Participants with Adverse Events, Number of Participants with Serious Adverse Events and 11 more. Started Oct 2024; status: completed.
02
Drugs
GSK3915393
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT06625489.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06625489.